Hepion Pharmaceuticals Management
Management criteria checks 2/4
Hepion Pharmaceuticals' CEO is Bob Foster, appointed in Jun 2016, has a tenure of 7.17 years. total yearly compensation is $725.83K, comprised of 73.5% salary and 26.5% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth €16.40K. The average tenure of the management team and the board of directors is 3.8 years and 3.6 years respectively.
Key information
Bob Foster
Chief executive officer
US$725.8k
Total compensation
| CEO salary percentage | 73.5% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.06% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$726k | US$533k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$700k | US$500k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$2m | US$400k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$621k | US$400k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$20m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$375k | US$312k | -US$18m |
Compensation vs Market: Bob's total compensation ($USD725.83K) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.
CEO
Bob Foster (65 yo)
7.2yrs
Tenure
US$725,833
Compensation
Dr. Robert T. Foster, also known as Bob, B.Sc (Pharm), Pharm D., Ph D., has been Chief Executive Officer at Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.) since October 3, 2018, Di...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.2yrs | US$725.83k | 0.062% $ 16.4k | |
| Chief Financial Officer | 7.4yrs | US$495.33k | 0.020% $ 5.2k | |
| Chief Medical Officer | 2.5yrs | US$578.00k | no data | |
| Chief Operating Officer | 1.2yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Senior Vice President of Drug Development | 3.8yrs | no data | no data | |
| Senior Vice President of Clinical Pharmacology | 3.8yrs | no data | no data | |
| Part-Time Consultant | 5.7yrs | US$34.62k | no data | |
| Scientific Advisory Board Chair & Consultant Medical Director | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
65yo
Average Age
Experienced Management: 336's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$725.83k | 0.062% $ 16.4k | |
| Scientific Advisory Board Chair & Consultant Medical Director | 4yrs | no data | no data | |
| Independent Director | 10.3yrs | US$86.00k | 0.0092% $ 2.4k | |
| Independent Chairman of the Board | 10.3yrs | US$102.50k | 0.016% $ 4.2k | |
| Independent Director | 9.8yrs | US$77.90k | no data | |
| Independent Director | 3.2yrs | US$79.50k | 0.039% $ 10.4k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 7.1yrs | no data | no data | |
| Independent Director | 1.2yrs | US$30.92k | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 1.2yrs | US$30.92k | no data |
3.6yrs
Average Tenure
65yo
Average Age
Experienced Board: 336's board of directors are considered experienced (3.6 years average tenure).